Renal profiles of anticoagulants

Journal of Clinical Pharmacology

Volumn 52, Issue 7, 2012, Pages 964-975

  Harder, Sebastian ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Anticoagulants; dose adjustment; excretion; pharmacokinetics; renal insufficiency

Indexed keywords

ACENOCOUMAROL; AMIODARONE; ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; PHENPROCOUMON; QUINIDINE; RIVAROXABAN; TINZAPARIN; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; AGING; ANTICOAGULANT THERAPY; ANTICOAGULATION; AREA UNDER THE CURVE; CARDIOVASCULAR DISEASE; COMORBIDITY; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDICATION ERROR; META ANALYSIS (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; POLYPHARMACY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; STROKE; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT REFUSAL; VENOUS THROMBOEMBOLISM;

ACUTE CORONARY SYNDROME; AGED; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMORRHAGE; HUMANS; RENAL INSUFFICIENCY; RISK FACTORS; STROKE; VENOUS THROMBOEMBOLISM;

EID: 84863212103     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011409231     Document Type: Review

References (88)

1. Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med. 2004;164:2260-2265. (Pubitemid 39456437)
2. Jokhadar M, Wenger NK. Review of the treatment of acute coronary syndrome in elderly patients. Clin Interv Aging. 2009;4:435-444.
3. Robert-Ebadi H, Le Gal G, Righini M. Use of anticoagulants in elderly patients: practical recommendations. Clin Invest Med. 2009;4:165-177.
4. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117.
5. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133:141S-159S. (Pubitemid 351892966)
6. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133:160S-198S. (Pubitemid 351892967)
7. Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs. 2005;5:291-305. (Pubitemid 41306468)
8. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133:381S-453S. (Pubitemid 351894916)
9. Struijk-Mulder MC, Ettema HB, Verheyen CC, Buller HR. Comparing consensus guidelines on thromboprophylaxis in orthopedic surgery. J Thromb Haemost. 2010;8:678-683.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130: 461-470. (Pubitemid 29135798)
12. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266.
13. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for industry: pharmacokinetics in patients with impaired renal function - study design, data analysis, and impact on dosing and labeling. Rockville, Md: Center for Biologics Evaluation and Research (CBER). Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM072127.pdf. Accessed October 26, 2010.
14. Committee for Medicinal Products for Human Use. Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function. London, UK: EMEA; 2004. Available at: http://www.ema.europa.eu/pdfs/human/ewp/022502en.pdf. Accessed October 26, 2010.
15. Coresh J, Stevens LA, Levey AS. Chronic kidney disease is common: what do we do next? Nephrol Dial Transplant. 2008;23:1122-1125. (Pubitemid 351767537)
16. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67-76.
17. Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65:757-773.
18. Clark B. Biology of renal aging in humans. Adv Ren Replace Ther. 2000;7:11-21. (Pubitemid 30059190)
19. Moal V, Brunet P, Dou L, Morange S, Sampol J, Berland Y. Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant. 2003;18:1834-1841. (Pubitemid 37098556)
20. Wannamethee SG, Shaper AG, Lowe GD, Lennon L, Rumley A, Whincup PH. Renal function and cardiovascular mortality in elderly men: the role of inflammatory, procoagulant, and endothelial biomarkers. Eur Heart J. 2006;27:2975-2981. (Pubitemid 44950441)
21. Catena C, Zingaro L, Casaccio D, Sechi LA. Abnormalities of coagulation in hypertensive patients with reduced creatinine clearance. Am J Med. 2000;109:556-561.
22. Ocak G, Verduijn M, Vossen CY, et al. Chronic kidney disease stage 1-3 increases risk of venous thrombosis. J Thromb Haemost. 2010;8:2428-2435.
23. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA. 1995;274:29-34.
24. Long CL, Raebel MA, Price DW, Magid DJ. Compliance with dosing guidelines in patients with chronic kidney disease. Ann Pharmacother. 2004;38:853-858. (Pubitemid 38509067)
25. Baum S, Harder S. Appropriate dosing in patients with impaired renal function on medical wards before and after an educational intervention. Int J Clin Pharmacol Ther. 2010;48:29-35.
26. Sweileh WM, Janem SA, Sawalha AF, et al. Medication dosing errors in hospitalized patients with renal impairment: a study in Palestine. Pharmacoepidemiol Drug Saf. 2007;16:908-912. (Pubitemid 47333542)
27. van Dijk EA, Drabbe NR, Kruijtbosch M, De Smet PA. Drug dosage adjustments according to renal function at hospital discharge. Ann Pharmacother. 2006;40:1254-1260. (Pubitemid 44204953)
28. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002;36:1331-1336. (Pubitemid 34925265)
29. Falconnier AD, Haefeli WE, Schoenenberger RA, Surber C, Martin-Facklam M. Drug dosage in patients with renal failure optimized by immediate concurrent feedback. J Gen Intern Med. 2001;16:369-375. (Pubitemid 34205654)
30. Sellier E, Colombet I, Sabatier B, et al. Effect of alerts for drug dosage adjustment in inpatients with renal insufficiency. J Am Med Inform Assoc. 2009;16:203-210.
31. Limited Sandoz. Warfarin (warfarin sodium 3 mg tablets) summary of product of characteristics. Surrey, UK: Limited Sandoz; 2010. Available at: http://emc.medicines.org.uk/medicine/21578/. Accessed October 25, 2010.
32. Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet. 2008;47:565-594.
33. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009;20:912-921.
34. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010;56:823-831.
35. Bachmann K, Shapiro R, Mackiewicz J. Warfarin elimination and responsiveness in patients with renal dysfunction. J Clin Pharmacol. 1977;17:292-299. (Pubitemid 8082193)
36. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133:454S-545S. (Pubitemid 351892971)
37. Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44:1227-1246. (Pubitemid 41832565)
38. Dager WE, Kiser TH. Systemic anticoagulation considerations in chronic kidney disease. Adv Chronic Kidney Dis. 2010;17:420-427.
39. Sanofi-Aventis. Clexane (enoxaparin sodium) summary of product characteristics. Sanofi, UK: Sanofi-Aventis; 2010. Available at: http://www.sanofi-aventis.co.uk/products/Clexane-SPC.pdf. Accessed October 19, 2010.
40. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost. 1995;73:630-640.
41. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143:753-759. (Pubitemid 34595330)
42. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res. 2002;105:225-231. (Pubitemid 34260945)
43. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res. 1991;63:385-390.
44. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med. 2006;144:673-684. (Pubitemid 46780653)
45. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy. 2000;20:771-775. (Pubitemid 30457356)
46. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J. 2003;146:33-41. (Pubitemid 36851297)
47. Rabbat CG, Cook DJ, Crowther MA, et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care. 2005;20:357-363. (Pubitemid 41727595)
48. Lobo BL. Use of newer anticoagulants in patients with chronic kidney disease. Am J Health Syst Pharm. 2007;64:2017-2026. (Pubitemid 47530407)
49. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost. 2002;87:163-164.
50. Barras MA, Duffull SB, Atherton JJ, Green B. Individualized dosing of enoxaparin for subjects with renal impairment is superior to conventional dosing at achieving therapeutic concentrations. Ther Drug Monit. 2010;32:482-488.
51. Leo Laboratories Limited. Innohep (tinzaparin sodium 10000 IU/ml) summary of product characteristics. Buckinghamshire, UK: Leo Laboratories Limited; 2009. Available at: http://emc.medicines.org.uk/medicine/2623/. Accessed November 12, 2010.
52. Leo Laboratories Limited. Innohep (tinzaparin sodium 20000 IU/ml) summary of product characteristics. Buckinghamshire, UK: Leo Laboratories Limited; 2009. Available at: http://www.medicines.org.uk/EMC/medicine/5176/. Accessed October 26, 2010.
53. Aspen Europe GmbH. Fragmin (dalteparin sodium surgical and medical thromboprophylaxis) summary of product of characteristics. 2010. Available at: http://emc.medicines.org.uk/medicine/9150/. Accessed October 26, 2010.
54. Pharmacia Limited. Fragmin (dalteparin sodium for treatment of VTE) summary of product characteristics. 2010. Available at: http://emc.medicines. org.uk/medicine/9148/. Accessed October 26, 2010.
55. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th ed). Chest. 2008;133:546S-592S. (Pubitemid 351892972)
56. Walenga JM, Jeske WP, Samama MM, Frapaise FX, Bick RL, Fareed J. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs. 2002;11:397-407. (Pubitemid 34213393)
57. Donat F, Duret JP, Santoni A, et al. The pharmacokinetics of fondaparinux sodium in healthy volunteers. Clin Pharmacokinet. 2002;41(suppl 2):1-9. (Pubitemid 35155551)
58. Boneu B, Necciari J, Cariou R, et al. Pharmacokinetics and tolerance of the natural pentasaccharide (SR90107/Org31540) with high affinity to antithrombin III in man. Thromb Haemost. 1995;74:1468-1473. (Pubitemid 26018663)
59. Turpie AG, Lensing AW, Fuji T, Boyle DA. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis. 2009;20:114-121.
60. Glaxo Group Ltd. Arixtra (fondaparinux sodium 5mg, 7.5mg, 10mg injection) summary of product characteristics. Middlesex, UK: Glaxo Group Ltd; 2010. Available at: http://emc.medicines.org.uk/medicine/15937. Accessed November 24, 2010.
61. Fox KA, Bassand JP, Mehta SR, et al. Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. Ann Intern Med. 2007;147:304-310. (Pubitemid 351664557)
62. GlaxoSmithKline. Arixtra (fondaparinux sodium) prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2010. Available at: http://us.gsk.com/products/assets/us-arixtra.pdf. Accessed December 13, 2010.
63. Glaxo Group Ltd. Arixtra (fondaparinux sodium 2.5 mg/0.5ml injection) summary of product characteristics. Middlesex, UK: Glaxo Group Ltd; 2010. Available at: http://emc.medicines.org.uk/medicine/15123. Accessed October 25, 2010.
64. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
65. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292-303. (Pubitemid 47283865)
66. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47-59. (Pubitemid 350260888)
67. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386-399. (Pubitemid 351185753)
68. Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010;64:956-967.
69. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285-295. (Pubitemid 351508116)
70. Stangier J, Rathgen K, Stahle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259-268.
71. Dahl OE, Kurth AA, Rosencher N, et al. Dabigatran etexilate 150 mg once daily for the prevention of venous thromboembolism after total knee or hip replacement surgery in the elderly and those with moderate renal impairment. J Thromb Haemost. 2009;7(suppl 2):695-696. Abstract PP-WE-205.
72. Boehringer Ingelheim International GmbH. Pradaxa® (dabigatran etexilate) summary of product characteristics; 2009. Available at: http://www.medicines.org.uk/EMC/medicine/20760/SPC/Pradaxa+110+mg+hard+capsules/ . Accessed October 19, 2010.
73. Buller HR. Once-daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism. The Einstein-Extension study. Blood (ASH Annual Meeting Abstracts). 2009;114. Abstract LBA-2.
74. Bayer Schering Pharma AG. Xarelto® (rivaroxaban) summary of product characteristics. Berlin, Germany: Bayer Schering Pharma AG; 2009. Available at: http://www.xarelto.com/html/downloads/Xarelto-Summary-of-Product- Characteristics-May2009.pdf. Accessed February 2, 2011.
75. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-421. (Pubitemid 41393676)
76. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873-880. (Pubitemid 41803696)
77. Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. Drug Metab Dispos. 2009;37:1056-1064.
78. Kubitza D, Becka M, Mueck W, et al. Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban - an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010;70:703-712.
79. Bauer KA, Homering M, Berkowitz SD. Effects of age, weight, gender and renal function in a pooled analysis of four phase III studies of rivaroxaban for prevention of venous thromboembolism after major orthopedic surgery. Blood (ASH Annual Meeting Abstracts). 2008;112:166-167. Abstract 436.
80. Samama MM, Le Flem L, Guinet C, Perzborn E, Amiral J, Depasse F. Suitability of chromogenic anti-FXa methods to measure rivaroxaban in human plasma. J Thromb Haemost. 2009;7(suppl 2):693. Abstract PP-WE-199.
81. Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs. 2008;9:1020-1033.
82. Frost C, Yu Z, Nepal S, Mosqueda-Garcia R, Shenker A. Apixaban, an oral direct Factor Xa inhibitor: single-dose safety, pharmacokinetics and pharmacodynamics in healthy volunteers. J Thromb Haemost. 2007;5(suppl 1). Abstract P-M-665.
83. Frost C, Yu Z, Moore K, et al. Apixaban, an oral direct factor Xa inhibitor: multiple-dose safety, pharmacokinetics, and pharmacodynamics in healthy subjects. J Thromb Haemost. 2007;5(suppl 2). Abstract P-M-664.
84. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22.
85. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74-81.
86. Zhang D, He K, Raghavan N, et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009;37:1738-1748.
87. Leil TA, Feng Y, Zhang L, Paccaly A, Mohan P, Pfister M. Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther. 2010;88:375-382.
88. Harder S, Saal K, Blauth E, Beyer M, Gerlach FM. Appropriateness and surveillance of medication in a cohort of diabetic patients on polypharmacy. Int J Clin Pharmacol Ther. 2009;47:104-110.